Details for Patent: 11,261,447
✉ Email this page to a colleague
Which drugs does patent 11,261,447 protect, and when does it expire?
Patent 11,261,447 protects OXLUMO and is included in one NDA.
This patent has seven patent family members in five countries.
Summary for Patent: 11,261,447
| Title: | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| Abstract: | The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. |
| Inventor(s): | Erbe; David V. (Arlington, MA), McGregor; Tracy L. (Cambridge, MA) |
| Assignee: | Alnylam Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 16/630,800 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,261,447
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,261,447
| PCT Information | |||
| PCT Filed | July 12, 2018 | PCT Application Number: | PCT/US2018/041891 |
| PCT Publication Date: | January 17, 2019 | PCT Publication Number: | WO2019/014491 |
International Family Members for US Patent 11,261,447
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018301829 | ⤷ Try a Trial | |||
| Canada | 3069451 | ⤷ Try a Trial | |||
| European Patent Office | 3651775 | ⤷ Try a Trial | |||
| Japan | 2020526553 | ⤷ Try a Trial | |||
| Japan | 2023179412 | ⤷ Try a Trial | |||
| Japan | 7337044 | ⤷ Try a Trial | |||
| World Intellectual Property Organization (WIPO) | 2019014491 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
